Market research
ETON Eton Pharmaceuticals Inc
NASDAQ USD Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 2B
- P/E ratio
- 134.18
- Analyst target
- 71.5
- Dividend yield
- Not available
- Beta
- 0.9
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- Not available
- Market cap
- 2B
- P/E ratio
- 134.18
- Analyst target
- 71.5
- Dividend yield
- Not available
- Beta
- 0.9
About
About Eton Pharmaceuticals Inc
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Research context
Eton Pharmaceuticals Inc appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the ETON discussion.
5 years, 6 months ago
Eton Pharmaceuticals, Inc is currently in a long term downtrend where the price is trading 27.9% below its 200 day moving average.
From a valuation standpoint, the stock is 196.0% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 3965.0.
Eton Pharmaceuticals, Inc's total revenue sank by 82.4% to $81K since the same quarter in the previous year.
Its net income has dropped by 185.1% to $-8M since the same quarter in the previous year.
Finally, its free cash flow fell by 56.0% to $-7M since the same quarter in the previous year.
Based on the above factors, Eton Pharmaceuticals, Inc gets an overall score of 0/5.